NEWS SUMMARY: IAG, TELEFÓNICA. Markets doubtful awaiting Powell in Jackson Hole European stock markets closed better than they opened, with some indices like the FTSE 100 managing to end with slight gains, whereas the DAX and IBEX ended practically flat. In the STOXX 600, the sectors rising the most were Energy, Banks and Basic Materials, with the biggest drops coming in Media, Consumer Goods and Chemicals. On the macro side, in the euro zone August’s preliminary manufacturing PMI rose more tha...
COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: IAG, TELEFÓNICA. EUROPA: AIR LIQUIDE. Mercados dubitativos a la espera de Powell en Jacson Hole Ayer las bolsas europeas fueron de menos a más y algunos índices como el FTSE 100 lograron terminar con ligeras ganancias mientras que el DAX y el Ibex terminaron casi sin cambios. En el STOXX 600 los sectores que más subieron fueron Energía, Bancos y R. Básicos frente a las mayores caídas de Media, B. Consumo y Químicas. Por el lado macro, en Eurozona el...
NEWS SUMMARY: IAG. European stock markets outperform US counterparts Yesterday European stock markets once again performed well, widening the outperformance gap with the S&P 500 in this second half of the month. In the STOXX 600, the sectors rising the most were Autos, Consumer Goods and Chemicals (all more than +2.0%), compared to Real Estate, which was the only sector closing in the red, and the cyclicals Industrials and Energy (dragged down by the Brent rout), which rose the least. On the ma...
COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: IAG. Los índices europeos sacan ventaja a los americanos Ayer las bolsas europeas volvieron a hacerlo bien y aprovecharon para ampliar el mejor comportamiento relativo frente al S&P 500 en esta segunda mitad de mes. En el STOXX 600 los sectores que más subieron fueron Autos, B. Consumo y Químicas (todos más de un +2,0%) frente a Inmobiliario que fue el único que cerró negativo y los cíclicos Industria y Energía (lastrado por la caída del Brent) que ...
Sanofi: Information concerning the total number of voting rights and shares - July 2025 Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of €2,454,937,946Registered office : 46, avenue de la Grande Armée - 75017 Paris - FranceRegistered at the Paris Commercial and Companies Registry unde...
Sanofi: Informations relatives au nombre de droits de vote et d'actions - Juillet 2025 Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des Marchés Financiers SanofiSociété anonyme au capital de 2 454 937 946 euros Siège social : 46, avenue de la Grande Armée - 75017 Paris395 030 844 R.C.S. Paris DateNombre d’actions composant le capital Nombre réel de droits de vote (déduction faite des actions auto-détenues)Nombre théorique de droits de vote (y compris actions...
Press Release: Sanofi’s rilzabrutinib earns orphan designation in the EU for IgG4-related disease Sanofi’s rilzabrutinib earns orphan designation in the EU for IgG4-related disease Data from the positive Phase 2 study evaluating rilzabrutinib for the treatment of IgG4-related disease presented at EULAR 2025Additional orphan designation underscores Sanofi commitment to advancing new medicines in immune-mediated rare diseases Paris, August 14, 2025. The European Medicines Agency has granted orphan designation to rilzabrutinib, a reversible covalent Bruton’s tyrosine kinase (BTK) inhibitor, ...
Communiqué de presse : Le rilzabrutinib de Sanofi obtient la désignation de médicament orphelin dans l’UE pour la maladie liée aux IgG4 Le rilzabrutinib de Sanofi obtient la désignation de médicament orphelin dans l’UE pour la maladie liée aux IgG4 Données de l’étude positive de phase 2 évaluant le rilzabrutinib pour le traitement de la maladie liée aux IgG4 présentée à l’EULAR de 2025Cette nouvelle désignation de médicament orphelin souligne l’engagement de Sanofi en faveur du développement de nouveaux médicaments contre les maladies rares à médiation immunitaire Paris, le 14 août 2025. ...
Communiqué de presse : Sanofi finalise l’acquisition de Vigil Neuroscience, Inc. Sanofi finalise l’acquisition de Vigil Neuroscience, Inc. Paris, le 6 août 2025. Sanofi annonce la finalisation de (« Vigil »). Cette acquisition renforce le pipeline de Sanofi en neurologie avec le VG-3927, un nouvel agoniste oral de TREM2, qui sera évalué dans une étude clinique de phase 2 chez des patients atteints de la maladie d’Alzheimer. En outre, l’acquisition du pipeline préclinique de Vigil renforcera la recherche de Sanofi dans diverses maladies neurodégénératives. En juin 2024, Sanofi a réalisé u...
Press Release: Sanofi completes the acquisition of Vigil Neuroscience, Inc. Sanofi completes the acquisition of Vigil Neuroscience, Inc. Paris, August 6, 2025. Sanofi announces the completion of (“Vigil”). This acquisition strengthens Sanofi’s early-stage pipeline in neurology with VG-3927, a novel, oral, small-molecule TREM2 agonist, which will be evaluated in a phase 2 clinical study in patients with Alzheimer’s disease. In addition, the acquisition of Vigil’s preclinical pipeline will further strengthen Sanofi’s research in various neurodegenerative diseases. In June 2024, Sanofi ...
Two Directors at International Consolidated Airlines Group SA sold 150,000 shares at between 371p and 378p. The significance rating of the trade was 83/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's...
Rdos. 2T'25 vs 2T'24: Ventas: 8.862 M euros (+6,8% vs +6,3% BS(e)); EBIT: 1.680 M euros (+35,4% vs +15,1% BS(e) y +15,2% consenso). Rdos. 1S'25 vs 1S'24: Ventas: 15.906 M euros (+8,0% vs +7,7% BS(e)); EBIT: 1.878 M euros (+43,5% vs +24,2% BS(e) y +24,4% consenso).
Press release: Online availability of Sanofi’s half-year financial report for 2025 Online availability of Sanofi’s half-year financial report for 2025 Paris, July 31, 2025. Sanofi announces that its half-year financial report for the period ending June 30, 2025 is now available and has been filed with the French market regulator Autorité des marchés financiers (AMF) and submitted to the U.S. Securities and Exchange Commission (SEC) under form 6-K. This document may be found on the company’s corporate website: and downloaded from the “Investors” page, under the heading “Regulated Inform...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.